The pregnancy rates are of use in typical service during the first year
The contraceptive measures that will be used most often in the US, are oral contraceptives (28%), female sterilization (27.1%), male condoms (16.1%), Male sterilization (9.9%) , intrauterine devices (IUDs, 5.5%), so-called. watching (coitus interruptus, 5.2%), progestin injections (3.2%), vaginal Ringkontrazeptiva (2.4%), subdermal implants progestin (<1%), transdermal contraceptive patch (<1%), natural methods (periodic abstinence <1%) and barrier methods for women (<1%, comparison of current contraceptive methods). The pregnancy rates during the first year of use in a typical application less than 1% in methods not related to sexual activity, and without user intervention (IUP, subdermal progestogen implants, sterilization) about 6-9% with hormonal contraceptive methods not related to sexual activity, and with engaging the user (oral contraceptives, progestin injection, transdermal patch, vaginal ring) About 10% of methods related to sexual (eg. as condoms, diaphragms, natural methods, spermicides, coitus interruptus) pregnancy rates tend to be during the first year of application higher and decrease in the following years, as users are increasingly familiar with the chosen method of contraception. The fertility of women decreases with age. For fertile couples trying to conceive, the pregnancy rate is about 85% at 1 year, if no contraceptive method is used. Despite higher pregnancy rate condoms are recommended for each sexual intercourse because they protect against sexually transmitted diseases, especially HIV. The effective contraception is to use condoms in addition to the use of other contraceptive methods. In unsuccessful contraception have emergency contraception can prevent unwanted pregnancy. Emergency contraception should not be used for regular contraception. Comparison of current methods of contraception method pregnancy rate in the first year of use pregnancy rate in long-term use conditions for applying disadvantages (selection) With ideal application In typical use Hormonal Oral contraceptives * 0.3% occupied 9% 67% pill daily progestin pill: at the same time of day ingested fluid retention, irregular bleeding, breast tenderness, nausea and vomiting, headache, numerous interactions with other drugs combination drugs: increased risk of venous thromboembolism progestin preparations: similar at Kontrazeptionsimplantaten progestin injection 0.2% 6% 56% injection every 3 months amenorrhea, irregular bleeding, weight gain Subdermal implant progestin 0.05% 0.05% 84% implantation every 3 years amenorrhea, irregular bleeding transdermal patch 0.3% 9% 67% Weekly application and removal Similar to oral contraceptives Local irritation vaginal 0.3% 9% 67% Monthly application (vaginally inserted leads) and removal Similar to oral contraceptives barrier Zervixkappe with spermicides - k) 8% (higher in case of women who have given birth. be applied A. Must every time sexual intercourse 3 sizes (size depending on whether the woman was already pregnant) If ? 6 hours after sexual intercourse in the vagina remain if necessary vaginal irritation or ulceration at whereabouts> 48 hours ago condom man be 2% applied 18% 43% must in each intercourse composed of the partner is required allergic reactions condom, female 5% 21% 41% must be applied to any intercourse allergic reactions contraceptive sponge (containing spermicides that delays release who the) 9% for nulliparas 20% in women who have given birth to 12% of nulliparous 24% women who have given birth to 36% may need to be applied to any intercourse used 24 hours prior to sexual intercourse remain used must be ? 6 hours after intercourse allergic reactions, vaginal dryness or irritation diaphragm with spermicides are applied 6% 12% 57% must in each intercourse can be used must ? 6 hours before sexual intercourse used 6-24 hours h after intercourse Occasionally remain vaginal irritation increased incidence of urinary tract infections Other intrauterine levonorgestrel-releasing intrauterine device: 0.3-0.5% (LNg14 [3-year intrauterine]) or 0.2% (LNg20 [5-year intrauterine]) Copper -Intrauterinpessare (T380A): 0.6% levonorgestrel-releasing intrauterine device: the same as for ideal application copper intrauterine devices (T380A): 8% 78-80% levonorgestrel-releasing intrauterine device: insertion: 3 or 5 years (depending on type) copper -Intrauterinpessare (T380A): insertion every 10 years Spontaneous exit, Uterine perforation (rare) levonorgestrel-releasing intrauterine devices: irregular bleeding, amenorrhea copper intrauterine devices (T380A): increased blood loss during menstruation, pelvic pain Natural methods (periodic abstinence) 0.45% or higher, depending on the method 24% 47% exercise, effort and several steps are necessary for the more effective methods Systemic or significant local side effects are unlikely coitus interruptus 4% 22% 46% Must be applied to any sexual involvement of the partner is required sterilization, women 0.5% Same as with ideal application 100% intervention is required (usually in an operating room, but occasionally also performed in practice) should be regarded as irreversible decision on the safe side additional contraception in time, is in the waiting for the confirmation of sterility through an examination in practice (3 months) sterilization, male 0.15% Identical to ideal use 100% intervention (is carried out in practice) and a local anesthetic is required Should be regarded as irreversible decision precaution, additional contraceptive in time, is in the wait for sterility verification (3 months) * have Oral contraceptives besides the contraception more positive health effects. Condoms protect both partners from sexually transmitted diseases. N / A = not available.